Ionis Pharmaceuticals, Inc. (IONS) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $46.87 (-8.90%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 10, 2026 | Tiago Fauth | Raymond James | $104.00 | +121.9% |
| Feb 25, 2026 | Michael Ulz | Morgan Stanley | $95.00 | +102.7% |
| Dec 17, 2025 | Luca Issi | RBC Capital | $95.00 | +102.7% |
| Oct 8, 2025 | Justin Kim | Oppenheimer | $90.00 | +92.0% |
| Sep 23, 2025 | Gena Wang | Barclays | $82.00 | +75.0% |
| Sep 22, 2025 | Gary Nachman | Raymond James | $75.00 | +60.0% |
| Sep 3, 2025 | Kostas Biliouris | BMO Capital | $70.00 | +49.4% |
| Sep 2, 2025 | Gena Wang | Barclays | $78.00 | +66.4% |
| Sep 2, 2025 | Michael Ulz | Morgan Stanley | $71.00 | +51.5% |
| Sep 2, 2025 | Mitchell Kapoor | H.C. Wainwright | $95.00 | +102.7% |
| Aug 22, 2025 | Yanan Zhu | Wells Fargo | $82.00 | +75.0% |
| Oct 9, 2024 | Debjit Chattopadhyay | Guggenheim | $65.00 | +38.7% |
| Aug 2, 2024 | Kostas Biliouris | BMO Capital | $60.00 | +28.0% |
| Jul 24, 2024 | Mani Foroohar | Leerink Partners | $62.00 | +32.3% |
| Jul 22, 2024 | Akash Tewari | Jefferies | $77.00 | +64.3% |
| Jul 22, 2024 | Salveen Richter | Goldman Sachs | $33.00 | -29.6% |
| Jul 16, 2024 | Akash Tewari | Jefferies | $75.00 | +60.0% |
| Jun 27, 2024 | Paul Matteis | Stifel Nicolaus | $53.00 | +13.1% |
| Jun 17, 2024 | Luca Issi | RBC Capital | $70.00 | +49.4% |
| Jun 14, 2024 | William Pickering | Tudor Pickering | $44.00 | -6.1% |
Top Analysts Covering IONS
IONS vs Sector & Market
| Metric | IONS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.15 | 2.25 | 2.42 |
| Analyst Count | 39 | 8 | 18 |
| Target Upside | +58.7% | +16187.2% | +19.5% |
| P/E Ratio | -30.52 | 3.82 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $157M | $200M | $228M | 5 |
| 2026-12-31 | $191M | $244M | $279M | 5 |
| 2027-03-31 | $208M | $265M | $303M | 5 |
| 2027-06-30 | $242M | $309M | $353M | 5 |
| 2027-09-30 | $288M | $367M | $419M | 5 |
| 2027-12-31 | $351M | $447M | $511M | 5 |
| 2028-12-31 | $2.01B | $2.02B | $2.02B | 14 |
| 2029-12-31 | $2.33B | $2.75B | $3.26B | 9 |
| 2030-12-31 | $3.02B | $3.56B | $4.22B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-1.24 | $-1.05 | $-0.76 | 1 |
| 2026-12-31 | $-1.16 | $-0.98 | $-0.70 | 1 |
| 2027-03-31 | $-0.38 | $-0.32 | $-0.23 | 1 |
| 2027-06-30 | $-0.25 | $-0.21 | $-0.15 | 1 |
| 2027-09-30 | $-0.06 | $-0.05 | $-0.04 | 1 |
| 2027-12-31 | $0.09 | $0.12 | $0.14 | 1 |
| 2028-12-31 | $-3.77 | $1.17 | $5.02 | 10 |
| 2029-12-31 | $2.91 | $3.63 | $4.50 | 4 |
| 2030-12-31 | $5.19 | $6.47 | $8.03 | 4 |
Frequently Asked Questions
What is the analyst consensus for IONS?
The consensus among 39 analysts covering Ionis Pharmaceuticals, Inc. (IONS) is Buy with an average price target of $107.22.
What is the highest price target for IONS?
The highest price target for IONS is $104.00, set by Tiago Fauth at Raymond James on 2026-04-10.
What is the lowest price target for IONS?
The lowest price target for IONS is $30.00, set by Jason Gerberry at Bank of America Securities on 2022-02-01.
How many analysts cover IONS?
39 analysts have issued ratings for Ionis Pharmaceuticals, Inc. in the past 12 months.
Is IONS a buy or sell right now?
Based on 39 analyst ratings, IONS has a consensus rating of Buy (2.15/5) with a +58.7% upside to the consensus target of $107.22.
What are the earnings estimates for IONS?
Analysts estimate IONS will report EPS of $-1.05 for the period ending 2026-09-30, with revenue estimated at $200M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.